All Articles: Health Sciences
Findings open new opportunities to seek BioB inhibitors to treat infections with M. tuberculosis and other pathogens.
Initial preclinical studies showed YCT-529 was 99% effective and 100% reversible with no side effects.
Findings can be used to decrease the negative impact on drug discovery of compounds that cause non-specific cell injury.
Research continues in collaboration with researchers at Harvard Medical School